Michael Rudnicki
Fundador en SATELLOS BIOSCIENCE INC. .
Fortuna: 1 M $ al 30/04/2024
Cargos activos de Michael Rudnicki
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SATELLOS BIOSCIENCE INC. | Fundador | 01/01/2018 | - |
Corporate Officer/Principal | - | - | |
Director/Miembro de la Junta | - | 05/12/2021 | |
Director Técnico/Científico/I+D | 01/05/2018 | - | |
University of Ottawa | Corporate Officer/Principal | - | - |
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute Hospital/Nursing ManagementHealth Services The Ottawa Hospital Research Institute is based in Ottawa, CA. The Canadian company provides world-class care with compassionate people. | Corporate Officer/Principal | - | - |
Stem Cell Network | Corporate Officer/Principal | - | - |
Historial de carrera de Michael Rudnicki
Antiguos cargos conocidos de Michael Rudnicki.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Verio Therapeutics, Inc.
Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Fundador | - | - |
The Ontario Institute For Regenerative Medicine
The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | - | - |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | 01/01/2018 | - |
Director Técnico/Científico/I+D | 01/01/2018 | - | |
Fundador | 01/01/2018 | - | |
FATE THERAPEUTICS, INC. | Fundador | 27/04/2007 | - |
Formación de Michael Rudnicki.
University of Ottawa | Doctorate Degree |
Estadísticas
Internacional
Canadá | 8 |
Estados Unidos | 2 |
Operativa
Founder | 4 |
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Sectorial
Health Technology | 5 |
Consumer Services | 2 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
FATE THERAPEUTICS, INC. | Health Technology |
SATELLOS BIOSCIENCE INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute Hospital/Nursing ManagementHealth Services The Ottawa Hospital Research Institute is based in Ottawa, CA. The Canadian company provides world-class care with compassionate people. | Health Services |
Verio Therapeutics, Inc.
Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Health Technology |
The Ontario Institute For Regenerative Medicine
The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Commercial Services |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
Stem Cell Network |
- Bolsa de valores
- Insiders
- Michael Rudnicki
- Experiencia